Anavex Life Sciences Corp. Stock
Anavex Life Sciences Corp. Stock price
Key metrics
| Market capitalization | $752.31m |
| Enterprise Value | $620.12m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 6.25 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-52.88m |
| Free Cash Flow (TTM) Free Cash Flow | $-30.81m |
| Cash position | $132.19m |
Is Anavex Life Sciences Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
Anavex Life Sciences Corp. Stock Analysis
Analyst Opinions
3 Analysts have issued a Anavex Life Sciences Corp. forecast:
Analyst Opinions
3 Analysts have issued a Anavex Life Sciences Corp. forecast:
Financial data from Anavex Life Sciences Corp.
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -53 -53 |
5%
5%
|
EBIT (Operating Income) EBIT | -53 -53 |
5%
5%
|
| Net Profit | -43 -43 |
9%
9%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Anavex Life Sciences Corp. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anavex Life Sciences Corp. Stock News
Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Christopher Missling |
| Employees | 42 |
| Founded | 2004 |
| Website | www.anavex.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
